专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

WO2017058784A1 TYPING AND ASSEMBLING DISCONTINUOUS GENOMIC ELEMENTS 审中-公开
标题翻译：类型和组装不连续的基因元素
公开(公告)号：WO2017058784A1
公开(公告)日：2017-04-06
申请号：PCT/US2016/053943
申请日：2016-09-27
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
发明人： REN, Bing , DIXON, Jesse , SELVARAJ, Siddarth
IPC分类号： C12Q1/68 , G06F19/26
CPC分类号： C12Q1/68 , C12Q1/6841 , G06F19/18 , G06F19/26 , C12Q2521/301 , C12Q2523/101 , C12Q2563/131
摘要： This invention relates to methods and kits for typing and assembling discontinuous genomic elements.
摘要翻译：本发明涉及用于分型和组装不连续基因组元件的方法和试剂盒。

42. 发明申请

WO2017051251A1 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS 审中-公开
标题翻译： 3-羟基喹唑啉-2,4-二酮衍生物及其作为核酸调节剂的用途
公开(公告)号：WO2017051251A1
公开(公告)日：2017-03-30
申请号：PCT/IB2016/001473
申请日：2016-09-26
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
发明人： GAHMAN, Timothy , SHIAU, Andrew , KOLODNER, Richard
IPC分类号： C07D239/96 , C07D471/04 , C07D403/12 , A61K31/517 , A61K31/519 , A61P35/00 , C07D401/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
CPC分类号： C07D487/04 , C07D239/96 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
摘要： Described inter alia are compounds according to formula (I): or a pharmaceutically acceptable salt thereof, and uses in methods for the modulation of flap endonuclease 1 (FENl), Xeroderma Pigmentosum Complementation Group G protein (XPG), Exonuclease 1 (EXOl) and/or GEN1.
摘要翻译：尤其是根据式（I）的化合物或其药学上可接受的盐，以及用于调节皮瓣内切核酸酶1（FEN1），皮肤色素白粉病互补组G蛋白（XPG），外切核酸酶1（EXO1）和 /或GEN1。

43. 发明申请

WO2017040790A1 ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译：抗PD-1抗体及其使用方法
公开(公告)号：WO2017040790A1
公开(公告)日：2017-03-09
申请号：PCT/US2016/049913
申请日：2016-09-01
申请人： AGENUS INC. , LUDWIG INSTITUTE FOR CANCER RESEARCH LTD , MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： VAN DIJK, Marc , MUNDT, Cornelia, Anne , RITTER, Gert , WOLCHOK, Jedd, David , MERGHOUB, Taha , ZAPPASODI, Roberta , HOLMGAARD, Rikke, Bæk , SCHAER, David , SAVITSKY, David, Adam , WILSON, Nicholas, Stuart
IPC分类号： C07K16/28 , A61K39/00
CPC分类号： C07K16/2818 , A61K2039/507 , C07K16/2803 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/92
摘要： The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
摘要翻译：本公开提供特异性结合人PD-1并拮抗PD-1功能的抗体。还提供了包含这些抗体的药物组合物，编码这些抗体的核酸，用于制备这些抗体的表达载体和宿主细胞，以及使用这些抗体治疗受试者的方法。

44. 发明申请

WO2013131019A1 IASPP PHOSPHORYLATION AND METASTATIC POTENTIAL 审中-公开
标题翻译： IASPP磷酸化和分解潜能
公开(公告)号：WO2013131019A1
公开(公告)日：2013-09-06
申请号：PCT/US2013/028696
申请日：2013-03-01
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. , CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
发明人： LU, Xin , LU, Min
IPC分类号： C07K16/00 , C07K14/00 , G01N33/574 , G06F19/00 , A61P35/00
CPC分类号： G01N33/57496 , A61K2039/505 , C07K14/4703 , C07K14/4746 , C07K16/18 , C07K16/30 , C07K16/44 , C07K2317/34 , C07K2317/76 , G01N2333/4704 , G01N2333/4748 , G01N2440/14 , G01N2800/56 , G06F19/00 , G16H50/30
摘要： Described herein are methods of evaluating metastatic potential of a cancer based on the phosphorylation state and/or intracellular localization of iASPP. Therapeutic regimens designed based on the results of the diagnostic methods are also provided.
摘要翻译：本文描述了基于iASPP的磷酸化状态和/或细胞内定位来评估癌症的转移潜能的方法。还提供了基于诊断方法结果设计的治疗方案。

45. 发明申请

WO2012088414A1 LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF 审中-公开
标题翻译：非质子陶瓷的制备及其用途
公开(公告)号：WO2012088414A1
公开(公告)日：2012-06-28
申请号：PCT/US2011/066840
申请日：2011-12-22
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. , CERUNDOLO, Vincenzo , EASTMAN, Simon
发明人： CERUNDOLO, Vincenzo , EASTMAN, Simon
IPC分类号： A61K39/00 , A61K39/39
CPC分类号： A61K9/1272 , A61K9/1277 , A61K39/0011 , A61K39/39 , A61K45/06 , A61K2039/55555
摘要： The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.
摘要翻译：本发明提供在其双层内含有非糖基神经酰胺的脂质体及其组合物。这些脂质体在体外和体内激活鼠iNKT细胞并诱导树突细胞（DC）成熟，其效力与其相应的可溶性非糖皮质神经酰胺相当。还提供了使用本发明的脂质体和组合物治疗疾病的方法。

46. 发明申请

WO2011045341A1 IDO INHIBITORS AND THERAPEUTIC USES THEREOF 审中-公开
标题翻译： IDO抑制剂及其治疗用途
公开(公告)号：WO2011045341A1
公开(公告)日：2011-04-21
申请号：PCT/EP2010/065337
申请日：2010-10-13
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD , ROEHRIG, Ute , LOAY, Awad , MICHIELIN, Olivier , VAN DEN EYNDE, Benoit , PILOTTE, Luc , STROOBANT, Vincent , LARRIEU, Pierre , VOGEL, Pierre , ZOETE, Vincent
发明人： ROEHRIG, Ute , LOAY, Awad , MICHIELIN, Olivier , VAN DEN EYNDE, Benoit , PILOTTE, Luc , STROOBANT, Vincent , LARRIEU, Pierre , VOGEL, Pierre , ZOETE, Vincent
IPC分类号： C07C251/22 , A61K31/135 , A61P43/00
CPC分类号： C07C251/22
摘要： Compounds of formula (I) in which R 1 , R 2 and R 3 , which may be the same or different, represent alkyl C 1-6 , cycloalkyl C3 - 7, aryl or NHR 4 , wherein R 4 may represent any of the values that any of R 1 , R 2 or R 3 may represent; additionally, R 3 may represent hydrogen, and pharmaceutically acceptable salts thereof, and their therapeutic use, eg in the treatment of cancer.
摘要翻译：式（I）化合物，其中R 1，R 2和R 3可以相同或不同，表示烷基C 1-6，环烷基C 3-7，芳基或NHR 4，其中R 4可以表示任何R 1， R2或R3可以表示; 此外，R3可以代表氢，及其药学上可接受的盐，以及它们的治疗用途，例如用于治疗癌症。

47. 发明申请

WO2011040973A2 TNF-IMMUNOCONJUGATES WITH FIBROBLAST ACTIVATION PROTEIN ANTIBODIES AND METHODS AND USES THEREOF 审中-公开
标题翻译：具有成纤维细胞活化蛋白抗体的TNF-免疫偶联物及其方法和用途
公开(公告)号：WO2011040973A2
公开(公告)日：2011-04-07
申请号：PCT/US2010/002661
申请日：2010-10-01
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. , BAUER, Stefan , WUEST, Thomas , RENNER, Christoph
发明人： BAUER, Stefan , WUEST, Thomas , RENNER, Christoph
IPC分类号： A61K47/48 , A61P35/00
CPC分类号： B82Y5/00 , A61K47/646 , A61K47/66
摘要： Protein-immunocoηjugates are provided, particularly TNF conjugates to antibodies and fragments thereof which bind to Fibroblast Activation Protein (FAP). TNF-FAP antibody conjugates are provided wherein the FAP antibody recognizes both human and mouse FAP. These immunoconjugates are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis, and more broadly in TNF responsive conditions and disorders, including cancer and hyperproliferative diseases. In addition, the FAP-immunoconjugates can be used for the diagnosis and treatment of FAP positive tumors such as pancreatic cancer, melanoma and sarcomas. The immunoconjugates, antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the present invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译：提供了蛋白 - 免疫偶联物，特别是与结合成纤维细胞活化蛋白（FAP）的抗体及其片段的TNF缀合物。提供了TNF-FAP抗体偶联物，其中FAP抗体识别人和小鼠FAP。这些免疫缀合物可用于诊断和治疗与激活的间质相关的病症，包括伤口愈合，上皮癌，骨关节炎，类风湿性关节炎，肝硬化和肺纤维化，更广泛地用于TNF反应性病症和病症，包括癌症和过度增殖性疾病。此外，FAP-免疫缀合物可用于诊断和治疗FAP阳性肿瘤，例如胰腺癌，黑素瘤和肉瘤。本发明的免疫缀合物，抗体，其可变区或CDR结构域序列及其片段也可以与化疗剂，免疫调节剂或抗癌剂和/或其他抗体或其片段组合用于治疗。 / p>

48. 发明申请

WO2011040972A1 ANTI-FIBROBLAST ACTIVATION PROTEIN ANTIBODIES AND METHODS AND USES THEREOF 审中-公开
标题翻译：抗纤维蛋白激活蛋白抗体及其方法及用途
公开(公告)号：WO2011040972A1
公开(公告)日：2011-04-07
申请号：PCT/US2010/002660
申请日：2010-10-01
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. , FISCHER, Eliane , BAUER, Stefan , WUEST, Thomas , RENNER, Christoph
发明人： FISCHER, Eliane , BAUER, Stefan , WUEST, Thomas , RENNER, Christoph
IPC分类号： C07K16/40 , A61K39/395 , C07K16/30
CPC分类号： C07K16/40 , C07K2317/21 , C07K2317/33 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESCl 1 and ESC 14 whose sequences are provided herein.
摘要翻译：提供了结合成纤维细胞激活蛋白（FAP）的特异性结合成员，特别是其抗体及其片段，特别是识别人和小鼠FAP。这些抗体可用于诊断和治疗与激活的基质相关的病症，包括伤口愈合，上皮癌，骨关节炎，类风湿性关节炎，肝硬化和肺纤维化。抗FAP抗体，其可变区或CDR结构域序列及其片段也可用于与化学治疗剂，免疫调节剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。这种抗体以本文提供其序列的新型抗体ESC1 1和ESC 14为例。

49. 发明申请

WO2010008427A1 TRYPTOPHAN CATABOLISM IN CANCER TREATMENT AND DIAGNOSIS 审中-公开
标题翻译：癌症治疗和诊断中的TRYPTOPHAN试剂
公开(公告)号：WO2010008427A1
公开(公告)日：2010-01-21
申请号：PCT/US2009/002250
申请日：2009-04-10
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. , VAN DEN EYNDE, Benoit , PILOTTE, Luc , DE PLAEN, Etienne
发明人： VAN DEN EYNDE, Benoit , PILOTTE, Luc , DE PLAEN, Etienne
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The unexpected expression of tryptophan 2,3-dioxygenase (TD02)in cancer cells and tumors has been established. Methods for diagnosing cancer based on the expression of TD02 are provided, as are methods for treating cancer and inhibiting the growth of cancer cells by inhibiting TD02, as well as pharmaceutical compositions.
摘要翻译：已经建立了色氨酸2,3-双加氧酶（TD02）在癌细胞和肿瘤中的意想不到的表达。提供了基于TD02的表达来诊断癌症的方法，以及通过抑制TD02以及药物组合物来治疗癌症并抑制癌细胞生长的方法。

50. 发明申请

WO2009131673A1 TARGETED TREATMENT FOR SUBJECTS WITH ESTROGEN RECEPTOR NEGATIVE AND PROGESTERONE RECEPTOR NEGATIVE BREAST CANCERS 审中-公开
标题翻译：雌激素受体负调节剂和孕激素受体负面乳腺癌患者的目标治疗
公开(公告)号：WO2009131673A1
公开(公告)日：2009-10-29
申请号：PCT/US2009/002483
申请日：2009-04-22
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. , GRIGORIADIS, Anita , CABALLERO, Otavia, L. , SIMPSON, Andrew John, George
发明人： GRIGORIADIS, Anita , CABALLERO, Otavia, L. , SIMPSON, Andrew John, George
IPC分类号： A61K39/00 , A61P27/02
CPC分类号： A61K39/0011 , C07K14/4748 , G01N33/57415 , G01N33/743 , G01N2333/723
摘要： Treatments for estrogen receptor and progesterone receptor negative breast cancer or estrogen receptor, progesterone receptor and c-erbB2 negative (triple negative) breast cancer are provided.
摘要翻译：提供雌激素受体和孕激素受体阴性乳腺癌或雌激素受体，孕酮受体和c-erbB2阴性（三阴性）乳腺癌的治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式